Statement of Need/Program Overview
Are you prepared to accurately assess the severity of atopic dermatitis (AD) across a diverse spectrum of age, comorbidities, and skin of color? Are you aware of the new and emerging targeted therapy options for mild to severe AD and the evolving physiological concepts behind their rationale? The goals of this activity are to educate pediatric and adult dermatologists, allergists, and dermatologic advanced practice providers (APPs) on the diagnosis and assessment of AD and its severity in children, adolescents, and adults; the mechanisms of action, efficacy, and safety of new and emerging targeted therapies for children, adolescents, and adults with mild to severe AD; and the clinical practice implications of emerging targeted therapies on symptoms and quality of life (QoL) in patients with mild to severe AD.

Target Audience
Dermatologists (including pediatric), allergists, dermatology nurses and nurse practitioners, dermatology physician assistants, and pharmacists

Educational Objectives
Upon completion of this educational activity, participants should be better able to: 
• ASSESS severity of atopic dermatitis (AD) in adults, adolescents, and children according to evidence-based recommendations
• EVALUATE the clinical efficacy and safety of new and emerging treatment options for mild to severe AD
• SELECT individualized treatment plans for adults, adolescents, and children with AD according to evidence-based recommendations and clinical data regarding new treatment options

Faculty
Andrew F. Alexis, MD, MPH
Vice-Chair for Diversity and Inclusion
Department of Dermatology
Weill Cornell Medicine
New York, NY

Linda Stein Gold, MD
Director of Clinical Research
Henry Ford Health System
Department of Dermatology ? Detroit, MI
Division Head Dermatology ? West Bloomfield, MI

Sponsorship & Support
This activity is jointly provided by Global Education Group and Spire Learning, LLC. 

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Spire Learning, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation 
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.5 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.

Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated.

Andrew F. Alexis, MD, MPH
Disclosures:
Consultant: AbbVie Inc; Allergan; Almirall; Amgen Inc; Arcutis Biotherapeutics; Bausch Health; Beiersdorf; Bristol Myers Squibb; Cassiopea, Inc; Dermavant Sciences, Inc; Galderma; Janssen Pharmaceuticals, Inc; LEO Pharma; L’Oreal; Menlo Therapeutics Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi; Scientis; Sol-Gel Technologies; UCB, Inc; Unilever; Valeant; Vyne Therapeutics Inc
Research Support: Almirall; Amgen Inc; Arcutis Biotherapeutics; Bausch Health; Bristol Myers Squibb; Cara Therapeutics; Galderma; LEO Pharma; Menlo Therapeutics Inc; Novartis Pharmaceuticals Corporation; Valeant 
Speakers Bureau: AstraZeneca; Pfizer Inc; Sanofi

Linda Stein Gold, MD
Disclosures: 
Consultant: AbbVie Inc; Amgen Inc; Arcutis Biotherapeutics; Bristol Myers Squibb; Dermavant Sciences, Inc; Eli Lilly and Company; Galderma; Incyte Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi; UCB, Inc
Research Support: AbbVie Inc; Amgen Inc; Arcutis Biotherapeutics; Dermavant Sciences, Inc; Eli Lilly and Company; Galderma; Incyte Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi; UCB, Inc
Honoraria: AbbVie Inc; Amgen Inc; Arcutis Biotherapeutics; Bristol Myers Squibb; Dermavant Sciences, Inc; Eli Lilly and Company; Galderma; Incyte Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi; UCB, Inc
Speakers Bureau: AbbVie Inc; Amgen Inc; Eli Lilly and Company; Galderma; Incyte Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi; UCB, Inc